Diabetic Polyneuropathy Clinical Trial
Official title:
Effect of Lower Body Positive Pressure Aerobic Training on Glycemic Indices and Quality of Life in Patients With Diabetic Polyneuropathy: Randomized Controlled Trial
Verified date | December 2023 |
Source | Umm Al-Qura University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Aging is a natural process that is frequently accompanied by chronic physical or mental health problems. Aging as well as a sedentary lifestyle behavior may produce identical pathological and morphological changes. Saudi population, especially elderly people assume sedentary lifestyle, with little physical activity is a strong predisposition for developing a disability that adversely affects many aspects of physical and mental functions; mainly mobility and the ability to perform the basic daily living activities (ADL); resulting finally in increased risk of independence, loss of functionality, and falls. Type 2 diabetes mellitus (T2DM) is a widespread chronic metabolic disorder, accounts for 90-95% of all patients with diabetes. It is one of the most life-threatening public health challenges in the world, characterized by long term complications that almost involves all systems of the body. Polyneuropathy is the most common symptomatic complication in patients with type 2 diabetes mellitus, found in 50 to 60 % of patients over the age of sixty, with the impaired glycemic control and deteriorated quality of life are among the most debilitating problems in patients with diabetic polyneuropathy.
Status | Completed |
Enrollment | 80 |
Est. completion date | October 20, 2021 |
Est. primary completion date | October 15, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 80 Years |
Eligibility | Inclusion Criteria: - Participants with diabetic polyneuropathy, - Diagnosed as having uncontrolled type 2 diabetes mellitus, with glycosylated hemoglobin (HbA1c) value between 7 and 11 and fasting glucose level ranged from 7.0 -11.1 mmol/L, - Age range from 60 and 80 years old, - Established type 2 diabetes mellitus duration over 10 years, treated only with oral anti-diabetic agents (not taking insulin), treated only with Biguanide alone or (Sulfonylureas plus Biguanide) oral anti-diabetic drugs combination, with pharmacological treatment had to be stable for at least 3 months before the study, - Cognitively competent and able to understand and follow instructions, capable of rationally interacting with others; understanding and answering the health related quality of life questionnaire (HRQL). Exclusion Criteria: - Type 1 DM, treated with insulin therapy or oral anti-diabetic therapy other than Biguanide alone or (Sulfonylureas plus Biguanide) combination, - Younger than 60 or older than 80 years old, - Patient with malnutrition (BMI < 21 kg/m2 or with recent weight loss > 5% body weight in the last month or > 10% in six months), - Patients with established hypertension (resting systolic blood pressure > 140 mmHg and diastolic blood pressure > 90 mmHg, - Active infection, drug abuse, participated in to an active rehabilitation program within last 6 months, - With severe chronic or uncontrolled comorbid condition as recent myocardial infarction, unstable angina, acute congestive heart failure, third degree heart block and uncontrolled arrhythmia. - With abnormal skin integrity e.g. wound or scares tissues or are on other complementary treatment, - History of serious cerebrovascular or cardiovascular diseases, and severe debilitating musculoskeletal problems) that could interfere with the evaluation or treatment efficacy and patient safety or precluded the patient from attending and completing the treatment sessions. |
Country | Name | City | State |
---|---|---|---|
Saudi Arabia | Umm Al-Qura University | Mecca |
Lead Sponsor | Collaborator |
---|---|
Umm Al-Qura University | King AbdulAziz City for Science and Technology |
Saudi Arabia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean change in the fasting blood glucose level "in mg/dl" at three months. | The fasting blood glucose (FBG) level "in mg/dl" will be evaluated in all participants at the baseline (at the beginning of the study) and at the end of the three-months Alter-G aerobic exercise training intervention (at the 12th week). | Baseline and post-three months aerobic exercise training intervention, (at the 12th week) | |
Primary | Mean change in the fasting blood glucose level in "mg/dl" at six months. | The fasting blood glucose (FBG) level "in mg/dl" will be evaluated in all participants at the baseline (at the beginning of the study) and at the end of the six-months (three months post-training cessation). | Baseline and after six months (three months post-training cessation; at the 24th week). | |
Primary | Mean changes in the glycosylated hemoglobin level (HbA1c) at three months. | The glycosylated hemoglobin level (HbA1c) will be evaluated in all participants at the baseline (at the beginning of the study) and at the end of the three-months Alter-G aerobic exercise training intervention (at the 12th week). | Baseline and post-three months aerobic exercise training intervention, (at the 12th week) | |
Primary | Mean changes in the glycosylated hemoglobin level (HbA1c) at six months. | The glycosylated hemoglobin level (HbA1c) will be evaluated in all participants at the baseline (at the beginning of the study) and at the end of the six-months (three months post-training cessation). | Baseline and after six months (three months post-training cessation; at the 24th week). | |
Secondary | Mean changes in the health-related quality of life at three months. | The health-related quality of life will be evaluated in all participants at the baseline (at the beginning of the study) and at the end of the three-months Alter-G aerobic exercise training intervention (at the 12th week). | Baseline and post-three months aerobic exercise training intervention, (at the 12th week) | |
Secondary | Mean changes in the health-related quality of life at six months. | The health-related quality of life will be evaluated in all participants at the baseline (at the beginning of the study) and at the end of the six-months (three months post-training cessation). | Baseline and after six months (three months post-training cessation; at the 24th week). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06040567 -
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
|
||
Completed |
NCT02423434 -
Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
|
||
Completed |
NCT05542901 -
Comparison of Joint Position Sense in Diabetic and Traumatic Transtibial Amputees
|
N/A | |
Withdrawn |
NCT01536236 -
Spinal Cord Stimulation for Diabetic Polyneuropathy
|
N/A | |
Active, not recruiting |
NCT01175928 -
Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy
|
Phase 1/Phase 2 | |
Completed |
NCT00993070 -
Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT00539175 -
Treatment of Painful Diabetic Neuropathy With Photon Stimulation
|
N/A | |
Completed |
NCT00278980 -
Effect of C-Peptide on Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT04593992 -
HTEMS Treatment of Diabetic Polyneuropathy
|
N/A | |
Completed |
NCT01465620 -
Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study
|
Phase 3 | |
Completed |
NCT01079325 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00406458 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Recruiting |
NCT06072573 -
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
|
Phase 3 | |
Recruiting |
NCT06071975 -
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
|
Phase 3 | |
Recruiting |
NCT05521737 -
Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01847937 -
Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT00476931 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00977483 -
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)
|
Phase 3 | |
Completed |
NCT01006915 -
Surgical Decompression for Diabetic Neuropathy in the Foot
|
N/A | |
Completed |
NCT00501202 -
Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).
|
Phase 2 |